Clouds. 40.2   F New York
AI-Powered News Summarizer
Top Stories

FDA issues updated guidance to address coronavirus variants

February 22, 2021. Summarized by summa-bot.

Compression ratio: 66.4%. 2 min read.

The US Food and Drug Administration has issued updated guidance for companies that plan to adapt their Covid-19 medical products -- including vaccines, tests and therapeutics -- to address the emergence of coronavirus variants.

(CNN)The US Food and Drug Administration has issued updated guidance for companies that plan to adapt their Covid-19 medical products -- including vaccines, tests and therapeutics -- to address the emergence of coronavirus variants.

The agency said in an announcement on Monday that it expects that "manufacturing information will remain generally the same" for authorized Covid-19 vaccines that may be updated to target variants.

The agency recommended that data from clinical immunogenicity studies be used to support any changes or updates to vaccines.

"For clinical data, the guidance recommends that a determination of effectiveness be supported by data from clinical immunogenicity studies, which would compare a recipient's immune response to virus variants induced by the modified vaccine against the immune response to the authorized vaccine," the agency noted in its announcement.

According to the FDA guidance, studies to assess the effectiveness of a Covid-19 vaccine's primary shot and booster dose should compare the immune response induced by the modified version of the vaccine to the original vaccine, and researchers should conduct a "booster study" in which the modified vaccine is administered to those who previously received the original vaccine.

"Each of the studies described above may be conducted in a single age group," the guidance said.

"The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants," Dr. Janet Woodcock, acting commissioner of the FDA, said in the announcement on Monday.

"We know the country is eager to return to a new normal and the emergence of the virus variants raises new concerns about the performance of these products," Woodcock said in part.

FDA officials said during Monday's call that some of the updated guidance for Covid-19 vaccines is modeled after what is already done for the development of seasonal influenza vaccines.

"We have experience with the fact that viruses change over time and seasonal influenza changes very frequently," Woodcock said during the call.

Summarizer is on Google News. Now you can get the latest AI summarized news on your favorite news platform.

Don't like Google News? We have an RSS Feed for you.

Suggestions